Evidence map›Paper›PMID 38125206›Full record

ArticleAmerican journal of preventive cardiology2024

Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study.

Khurram Nasir, Reed Mszar, Miguel Cainzos-Achirica, Gowtham R Grandhi, Tycho R Tromp, Rodrigo Alonso, Márcio S Bittencourt, Eric Bruckert, José Luis Díaz-Díaz, Antonio Gallo and 9 more

Open access · goldAbstract read
In one paragraph

Article in American journal of preventive cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 7 countries.

Khurram NasirHouston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA.
Reed MszarDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Miguel Cainzos-AchiricaDepartment of Cardiology, Hospital del Mar / Parc de Salut Mar, Barcelona, Spain.
Gowtham R GrandhiVirginia Commonwealth University Health Pauley Heart Center, Richmond, VA, USA.
Tycho R TrompDepartment of Vascular Medicine, Amsterdam UMC, location AMC, Amsterdam, the Netherlands.
Rodrigo AlonsoCenter for Advanced Metabolic Medicine and Nutrition, Santiago, Chile.
Márcio S BittencourtDivision of Internal Medicine, University Hospital, University of São Paulo, São Paulo, Brazil.
Eric BruckertSorbonne Université, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, APHP, Hôpital Pitié-Salpètriêre, Paris, France.
José Luis Díaz-DíazComplejo Hospitalario Universitario, Hospital Abente y Lago, A Corūna, Spain.
Antonio GalloSorbonne Université, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, APHP, Hôpital Pitié-Salpètriêre, Paris, France.
G Kees HovinghDepartment of Vascular Medicine, Amsterdam UMC, location AMC, Amsterdam, the Netherlands.
Marcio H MinameHeart Institute (INCOR), University of São Paulo Medical School Hospital, São Paulo, Brazil.
Ovidio Muñiz-GrijalvoInternal Medicine Department, Hospital Virgen del Rocío, Sevilla, Spain.
Jing PangSchool of Medicine, University of Western Australia, Department of Cardiology, Royal Perth Hospital, Western Australia, Australia.
Leopoldo Perez de IslaCardiology Department, Hospital Clinico San Carlos, IDISSC, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Eric J G SijbrandsDepartment of Internal Medicine, Section Pharmacology, Vascular and Metabolic Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
Gerald F WattsSchool of Medicine, University of Western Australia, Department of Cardiology, Royal Perth Hospital, Western Australia, Australia.
Pedro MataFundación Hipercolesterolemia Familiar, Madrid, Spain.
Raul D SantosHeart Institute (INCOR), University of São Paulo Medical School Hospital, São Paulo, Brazil.
Amsterdam University Medical Centers · NLHouston Methodist · USInserm · FRThe University of Western Australia · AUUniversidade de São Paulo · BRAdvanced Center for Chronic Diseases · CLComplexo Hospitalario Universitario A Coruña · ESErasmus MC · NLHospital Clínico San Carlos · ESHospital Universitário da Universidade de São Paulo · BRHospital Universitario Virgen del Rocío · ESVirginia Commonwealth University · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Individuals with familial hypercholesterolemia (FH) are at an increased risk for coronary artery disease (CAD). While prior research has shown variability in coronary artery calcification (CAC) among those with FH, studies with small sample sizes and single-center recruitment have been limited in their ability to characterize CAC and plaque burden in subgroups based on age and sex. Understanding the spectrum of atherosclerosis may result in personalized risk assessment and tailored allocation of costly add-on, non-statin lipid-lowering therapies. We aimed to characterize the presence and burden of CAC and coronary plaque on computed tomography angiography (CTA) across age- and sex-stratified subgroups of individuals with FH who were without CAD at baseline. Methods: We pooled 1,011 patients from six cohorts across Brazil, France, the Netherlands, Spain, and Australia. Our main measures of subclinical atherosclerosis included CAC ranges (i.e., 0, 1-100, 101-400, >400) and CTA-derived plaque burden (i.e., no plaque, non-obstructive CAD, obstructive CAD). Results: Ninety-five percent of individuals with FH (mean age: 48 years; 54% female; treated LDL-C: 154 mg/dL) had a molecular diagnosis and 899 (89%) were on statin therapy. Overall, 423 (42%) had CAC=0, 329 (33%) had CAC 1-100, 160 (16%) had CAC 101-400, and 99 (10%) had CAC >400. Compared to males, female patients were more likely to have CAC=0 (48% [ Conclusion: In this large, multi-national study, we found substantial age- and sex-based heterogeneity in CAC and plaque burden in a cohort of predominantly statin-treated individuals with FH, with evidence for a less pronounced increase in atherosclerosis among female patients. Future studies should examine the predictors of resilience to and long-term implications of the differential burden of subclinical coronary atherosclerosis in this higher risk population.

Indexed as

Atherosclerotic cardiovascular diseaseCoronary artery calciumFamilial hypercholesterolemiaLow-density lipoprotein cholesterolPlaque burden

Identifiers

PMID38125206
PMCPMC10730992
OpenAlexW4388923854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.